全文获取类型
收费全文 | 268057篇 |
免费 | 25306篇 |
国内免费 | 9104篇 |
专业分类
耳鼻咽喉 | 1454篇 |
儿科学 | 6004篇 |
妇产科学 | 3791篇 |
基础医学 | 42569篇 |
口腔科学 | 4952篇 |
临床医学 | 21007篇 |
内科学 | 53268篇 |
皮肤病学 | 4181篇 |
神经病学 | 18432篇 |
特种医学 | 4885篇 |
外国民族医学 | 60篇 |
外科学 | 19108篇 |
综合类 | 37906篇 |
现状与发展 | 37篇 |
一般理论 | 3篇 |
预防医学 | 14632篇 |
眼科学 | 3571篇 |
药学 | 33277篇 |
80篇 | |
中国医学 | 11526篇 |
肿瘤学 | 21724篇 |
出版年
2024年 | 206篇 |
2023年 | 4142篇 |
2022年 | 5393篇 |
2021年 | 10317篇 |
2020年 | 9938篇 |
2019年 | 10349篇 |
2018年 | 9921篇 |
2017年 | 9968篇 |
2016年 | 10123篇 |
2015年 | 11455篇 |
2014年 | 17416篇 |
2013年 | 19128篇 |
2012年 | 17374篇 |
2011年 | 19957篇 |
2010年 | 16477篇 |
2009年 | 15818篇 |
2008年 | 14931篇 |
2007年 | 13651篇 |
2006年 | 12149篇 |
2005年 | 10501篇 |
2004年 | 8978篇 |
2003年 | 7553篇 |
2002年 | 5942篇 |
2001年 | 5210篇 |
2000年 | 4279篇 |
1999年 | 3665篇 |
1998年 | 2796篇 |
1997年 | 2595篇 |
1996年 | 2222篇 |
1995年 | 2243篇 |
1994年 | 1977篇 |
1993年 | 1722篇 |
1992年 | 1464篇 |
1991年 | 1256篇 |
1990年 | 1091篇 |
1989年 | 950篇 |
1988年 | 853篇 |
1987年 | 708篇 |
1986年 | 687篇 |
1985年 | 1096篇 |
1984年 | 1058篇 |
1983年 | 704篇 |
1982年 | 845篇 |
1981年 | 666篇 |
1980年 | 587篇 |
1979年 | 474篇 |
1978年 | 384篇 |
1977年 | 301篇 |
1976年 | 276篇 |
1975年 | 174篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Saudi Pharmaceutical Journal》2022,30(6):669-678
BackgroundIschemia reperfusion (I/R) play an imperative role in the expansion of cardiovascular disease. Sinomenine (SM) has been exhibited to possess antioxidant, anticancer, anti-inflammatory, antiviral and anticarcinogenic properties. The aim of the study was scrutinized the cardioprotective effect of SM against I/R injury in rat.MethodsRat were randomly divided into normal control (NC), I/R control and I/R + SM (5, 10 and 20 mg/kg), respectively. Ventricular arrhythmias, body weight and heart weight were estimated. Antioxidant, inflammatory cytokines, inflammatory mediators and plasmin system indicator were accessed.ResultsPre-treated SM group rats exhibited the reduction in the duration and incidence of ventricular fibrillation, ventricular ectopic beat (VEB) and ventricular tachycardia along with suppression of arrhythmia score during the ischemia (30 and 120 min). SM treated rats significantly (P < 0.001) altered the level of antioxidant parameters. SM treatment significantly (P < 0.001) repressed the level of creatine kinase MB (CK-MB), creatine kinase (CK) and troponin I (Tnl). SM treated rats significantly (P < 0.001) repressed the tissue factor (TF), thromboxane B2 (TXB2), plasminogen activator inhibitor 1 (PAI-1) and plasma fibrinogen (Fbg) and inflammatory cytokines and inflammatory mediators.ConclusionOur result clearly indicated that SM plays anti-arrhythmia effect in I/R injury in the rats via alteration of oxidative stress and inflammatory reaction. 相似文献
2.
3.
4.
5.
6.
Osama Y Safdar Rana M Baghdadi Sereen A Alahmadi Bana E Fakieh Amaal M Algaydi 《World Journal of Clinical Pediatrics》2022,11(1):14-26
Whether the underlying mutations are homozygous, heterozygous, or co-inherited with other hemoglobinopathies, sickle cell disease is known to afflict the kidneys, leading to the clinical entity known as sickle cell nephropathy (SCN). Although common, SCN remains diagnostically elusive. Conventional studies performed in the context of renal disorders often fail to detect early stage SCN. This makes the quest for early diagnosis and treatment more challenging, and it increases the burden of chronic kidney disease-related morbidity among patients. Novel diagnostic tools have been employed to overcome this limitation. In this study, we discuss various biomarkers of SCN, including those employed in clinical practice and others recently identified in experimental settings, such as markers of vascular injury, endothelial dysfunction, tubulo-glomerular damage, and oxidative stress. These include kidney injury molecule-1, monocyte chemoattractant protein-1, N-acetyl-B-D-glucosaminidase, ceruloplasmin, orosomucoid, nephrin, and cation channels, among others. Furthermore, we explore the potential of novel biomarkers for refining diagnostic and therapeutic approaches and describe some obstacles that still need to be overcome. We highlight the importance of a collaborative approach to standardize the use of promising new biomarkers. Finally, we outline the limitations of conventional markers of renal damage as extensions of the pathogenic process occurring at the level of the organ and its functional subunits, with a discussion of the expected pattern of clinical and biochemical progression among patients with SCN. 相似文献
7.
《European journal of medical genetics》2022,65(11):104609
BackgroundGastrointestinal stromal tumors have been detected in 25% of the necropsies performed on NF1 patients, but have been reported only in 7% of NF1 patients in the largest series. Such data imply an important gap between the true presence of tumors and those diagnosed. Few genotype-phenotype relationships have been described but to date none referring to abdominal tumors.ObjectivesEvaluate retrospectively the efficacy of a regular and proactive follow-up of NF1 patients to early diagnose abdominal tumors and report their mutations.MethodsCohort study performed between 2010 and 2020, with 43 NF1 adult patients followed at our Dermatology department.ResultsEight abdominal tumors were diagnosed in six patients, meaning that 14% of the followed patients developed an abdominal tumor. Five patients (83%) were asymptomatic. Five (83.3%) had a family history of NF1 with abdominal tumors (patients 1,2 and 3,4,5 were relatives).ConclusionsAlthough currently gastrointestinal routine screening investigations for asymptomatic patients are not recommended in the guidelines, the family aggregation in our series suggests it should be considered a close follow-up of the relatives of a patient with an NF1-related abdominal tumor. Also, for the first time, two mutations [c.2041C > T (p.Arg681Ter) and c.4537C > T (p.Arg1513*)] have been associated with family aggregation of abdominal tumors in NF1 patients. 相似文献
8.
9.
《Nutrition, metabolism, and cardiovascular diseases : NMCD》2022,32(1):151-159
Background & aimsTo determine the trends of self-reported non-adherence rates among adults taking Type 2 medicines (T2D) medicines between 2017 and 2019 and to identify the patterns for the frequently reported reasons for non-adherence in the United States.Methods & resultsData from the National Health and Wellness Survey, a self-administered, internet-based cross-sectional survey of US adults from 2017 to 2019 was used. Non-adherence was measured using the self-reported Medication Adherence Reasons Scale (MAR-Scale). Frequencies were used to identify the reasons for non-adherence for insulin and non-insulin therapies for T2D.Data were obtained from 2983 respondents in 2017, 5416 in 2018, and 5268 in 2019. Based on the MAR-Scale, the self-reported medication non-adherence rate was 25% in 2017, 21% in 2018, and 27% in 2019. The most common reason for non-adherence across all the three years was simple forgetfulness, yet patients reported the lowest mean number of days missing medication for that reason. Though less frequently reported, non-adherence lasted longer when patient did not know how to take their medicines, cost was a reason, or had concerns about the long term effects of the medicines.ConclusionsWith no significant improvement in adherence with T2D medicines over time, regardless of better awareness and extensive diabetes education, focus should be on individualized non-adherence reasons-based interventions. 相似文献
10.